Nucana Plc (NCNA) has released an update.
NuCana plc has successfully regained compliance with the Nasdaq’s minimum bid price requirement after its American Depositary Shares maintained a closing bid price of at least $1.00 for 10 consecutive business days. The company had previously been granted an additional period to meet this requirement following a notification of non-compliance. NuCana’s focus is on enhancing cancer treatment by developing ProTides, which aim to improve the efficacy and safety of chemotherapy agents.
For further insights into NCNA stock, check out TipRanks’ Stock Analysis page.
